Impact of hospital experience on the quality of tyrosine kinase inhibitor response monitoring and consequence for chronic myeloid leukemia patient survival

• Inge G.P. Geelen,
• Noortje Thielen,
• Jeroen J.W.M. Janssen,
• Mels Hoogendoorn,
• Tanja J.A. Roosma,
• Sten P. Willemsen,
• Peter J.M. Valk,
• Otto Visser,
• Jan J. Cornelissen,
• Peter E. Westerweel

Affiliations

Inge G.P. Geelen

Department of Hematology, Albert Schweitzer Hospital, Dordrecht, the Netherlands

Noortje Thielen

Department of Hematology, VU University Medical Center, Amsterdam, the Netherlands;Department of Internal Medicine, Diakonessenhuis, Utrecht, the Netherlands

Jeroen J.W.M. Janssen

Department of Hematology, VU University Medical Center, Amsterdam, the Netherlands

Mels Hoogendoorn

Department of Hematology, Medical Center Leeuwarden, Dordrecht, the Netherlands

Tanja J.A. Roosma

Department of Hematology, VU University Medical Center, Amsterdam, the Netherlands

Sten P. Willemsen

Department of Biostatistics, Albert Schweitzer Hospital, Dordrecht, the Netherlands;Department of Biostatistics, Erasmus University Medical Center, Rotterdam, the Netherlands

Peter J.M. Valk

Department of Hematology, Erasmus University Medical Center, Rotterdam, the Netherlands

Otto Visser

Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, the Netherlands

Jan J. Cornelissen

Department of Hematology, Erasmus University Medical Center, Rotterdam, the Netherlands

Peter E. Westerweel

Department of Hematology, Albert Schweitzer Hospital, Dordrecht, the Netherlands